Exam 1 Flashcards

1
Q

What are prodrugs?

A

• inactive
• need to be biotransformed into active form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Half lives to reach steady state?

A

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Goal of fixed dosing

A

o Designed to generate plasma drug conc. w/in therapeutic range

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Factors that vary individually & how they affect drug’s therapeutic effect

A

o Physiology
o Pathoglogy
o Pharmacologic effects (drug interactions etc)

Above effects on PK are unpredictable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Drug & Disease Criteria for using Trial and error approach to dosing

A

Drugs
• Gas inhalants
• Ultrashort thiobarbituate anesthetics
• Rapid anticonvulsants
• Lidocaine in treatment of arrhythmias
• Drugs w/ large therapeutic window

Diseases
• Illnesses that are not serious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Types of Drugs to Use TDM

A

o Drugs that cause serious toxicity
o Steep dose response curve
o Poorly defined clinical end point
o Narrow therapeutic range
o Nonlinear pharmacokinetics
o combo drugs that may interact
o Very specific target therapeutic range

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Criteria for Using TDM

A

o Response to drug must match plasma conc.
o Must measure compound or metabolite or both depending on which produces therapeutic effect
o Drug must be measurable
o Assay available to detect drug rapidly & accurately

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When to Measure the Peak Vs the Trough

A

Peak
• short half-life drug
• If toxicity is concern

Trough
• short half-life drug
• If efficacy is concern

Either
• If drug has a long half life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Factors that may influence the incidence and significance of DDIs

A

o Relative doses of the interacting drugs
o Type of drug and condition being treated
o Dosage forms and routes of administration
o Duration of treatment

o Order of drug administration
o Multiple drug therapy
o Individual patient factors (liver/kidney dz)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Drugs w/ Low Therapeutic Index

A

o Beta-blockers
o Anesthetics
o Phenytoin
o Theophylline
o Digoxin
o Cyclosporine
o Phenobarbital
o Warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drug Drug Interactions Interfering w/ Absorption

A

Change in GI pH
• drug that makes pH basic when other drug needs acidic environment

Drug binding in GI tract
• Two drugs bind in GI tract and can’t be absorbed

Change in GI motility
• One drug changes motility -> decreases absorption of drug 2

Malabsorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drug Drug Interactions Interfering w/ Distribution

A

o Drug 1 displaces drug 2 from binding site
o Drug 1 can induce transporter of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drug Drug Interactions Interfering w/ Elimination-Metabolism

A

Induction of Metabolism
• Drug 1 induces hepatic microsomal enzymes (cytochrome P450 enzymes, CYPs) ->
• Drug 2 metabolized by the induced CYP isoform may have reduced efficacy/duration
OR
• Induction of metabolism could increase drug effect
• Occurs after 2-3wks
• After removal of drug 1, returns to normal after 2-3wks

Inhibition of Metabolism
• Can increase drug effect OR decrease
• Can happen directly after 1st dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Reporting Adverse Drug Reactions to FDA

A

o Adverse or non-efficacious
o Should be reported even if drug was used off-label

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drugs Prohibited in Food Animals

A

o Chloramphenicol
o Clenbuterol
o Diethylstilbestrol (DES)
o Dimetridazole, ipronidazole and other nitroimidazoles
o Furazolidone and nitrofurazone (except for approved topical use)
o Extralabel use of fluoroquinolones
o Glycopeptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drugs Prohibited Specifically In Dairy Cows

A

Sulfonamide drugs EXCEPT
• Sulfadimethoxine
• Sulfabromomethazine
• Sulfaethoxypyridazine

Phenylbutazone in 20mo or older

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Special Considerations for Using Cephalosporins in Food Animals

A

Prohibited in cattle, swine, chickens, turkeys for:
• disease prevention (ok for treating dz)
• At unapproved doses, frequencies, durations, or routes of administration

• If the drug is not approved for that species and production class

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Special Considerations for Using Adamantane and Neuraminidase inhibitors in Food Animals

A

o approved for treating or preventing influenza A.

o prohibited from extra‐label uses in chickens, turkeys, and ducks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Extra label use in food animals

A

o allowed if vet can establish extended withdrawal time to insure that the edible tissues are safe for human consumption
o Use FARAD for withdrawal time info
o Must: diagnose condition, maintain animals ID, establish extended withdrawal, ensure no illegal drug residues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Prescribing Human Drugs to food animals

A

can’t prescribe an approved human drug if there’s a drug approved for food‐producing animals
o Ex: if a drug approved for chickens is available, you must first use that drug to treat a sick cow before reaching for a drug approved for people
o Exceptions: animal drug does not contain active ingredient needed, required dosage, required conc., or is clinically ineffective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Extralabel Drug Use in companion animals

A

o In companion animals, you can prescribe an approved human drug for an extra‐label use even if an approved animal drug is available
o must keep records for 2 years or time required by federal or state law, whichever is longer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Scheduled Drugs

A

Schedule I
o No accepted medical use in US

Schedule II/IIN
o High potential for abuse
o Sever psychological or physiological dependency

Schedule III/IIIN
o Abuse less likely
o Moderate physical dependency
o High psychological dependency

Schedule IV
o Low potential for abuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Most Important Functions of Kidney

A

o Regulation of water & electrolytes
o Excretion of metabolic waste
o Regulation of arterial pressure
o Acid-base balance
o Regulation of 1,25 cholecalciferol
o EPO production
o Glucose synthesis

24
Q

Function of Glomerulus, Proximal Tubule, Loop of Henle, Distal Tubule

A

Glomerular Function
o GFR affects drug clearance
o Prevents protein loss into urine

Proximal Tubule Function
o Resorption of water
o Loss of solutes

Loop of Henle Function
o Dilutes urine
o Develops medullary conc. gradient

Distal Tubule
o Dilutes urine
o Resorps Na
o ALD
o Bicarb formation

25
Carbonic Anhydrase Inhibitor, Drug, area, MOA
o Acetazolamide o Works on proximal tubules Mechanism • Decreases H+
 • Decreased Na absorption via the Na+/H+ antiporter • K+ wasting and increased HCO3‐ secretion -> alkaline diuresis
26
Carbonic Anhydrase Inhibitor, Indications & Toxicity
Indications • Metabolic alkalosis • Glaucoma • Hyperkalemic periodic paralysis (equine) Toxicity • Allergen to those allergic to sulfonamide • Causes metabolic acidosis • Cause electrolyte disturbance
27
Osmotic Diuretics; Drug, area, MOA
o Mannitol o Mainly proximal tubule Mechanism • Expands extracellular fluid volume • Inhibit water & Na+ reabsorption in medullary collecting ducts • Increase inner medullary blood flow
28
Osmotic Diuretics; Indications & Toxicity
Indications • Relieve intratubular obstruction • Increase GFR, renal blood flow, urine production • Glaucoma Toxicity _ Acute • Rapid volume expansion -> • increased blood pressure and hyponatremia -> • may precipitate cardiac failure and pulmonary edema _ Chronic • Dehydration • Electrolyte disturbance
29
Loop Diuretics; Drug, area, MOA
• Furosemide • Loop of Henle Mechanism • Inhibit Na/K/Cl symporter • Increase prostaglandin release -> increase renal blood flow • Inhibits Ca & Mg reabsorption • Increases K & H+ excretion • Increases renin release • Increases venous compliance • Decrease R atrial P • Decrease pulmonary artery P
30
Loop Diuretics; Indications & Toxicity
Indications • Most commonly used diuretic • Treatment of edema due to cardiac, hepatic, or renal • Increased urine output in renal failure • Hypercalcemia • Hyperkalemia • Udder edema (cows) • Exercise induced pulmonary hemorrhage (horses) Toxicity • Additive risk for nephrotoxicity w/ other nephrotoxic drugs • Additive risk of ototoxicity • Hypokalemia • Dehydration
31
Loop Diuretics; Transport, Drug Interactions, Contraindications
Transport • Potent, rapid, short-lived • Action limited by amount of Na • Must be transported to loop by organic anion transporter Drug Interactions • Efficacy inhibited by NSAIDs Contraindications • Patients w/ anuria • Preexisting electrolyte or H2O abnormalities • Conditions that lead to electrolyte or H2O abnormalities • Hypotension • Hepatic encephalopathy
32
Thiazide Diuretics; Drug, area, MOA
Drugs o Chlorothiazide o Hydrochlorothiazide Sit of Action o Early distal tubule MOA o WEAK diuretic o Inhibits Na-Cl transporter o Enhances excretion of Na, Cl, H2O, K. Mg, P, Iodide, Bromide o Decreases Ca excretion (opposite of furosemide)
33
Thiazide Diuretics; Indications, Toxicity
Indications o Prevent calcium oxalate uroliths in dogs o Decrease PU/PD in diabetes insipidus o Used to enhance effects of diazoxide in treatment of insulinomas in dogs o Hyperkalemic periodic paralysis in horses Toxicity o Dehydration o Hypokalemia o GI effects o Alkalosis o Sulfonamide hypersensitivity o Exacerbate hyperglycemia
34
Aldosterone Antagonists; Drug, area, MOA
Drugs o Spironolactone Site o Distal tubules MOA o Inhibits ALD binding o Increase excretion of Na, Cl, H2O o Decrease excretion of K, ammonium, phosphate
35
Aldosterone Antagonists; Indications, Toxicity
Indications o w/ furosemide or ACE for CHF o w/ loop or thiazide diuretics to decrease K waisting o ascites Toxicity o Hyperkalemia o Dehydration o Metabolic acidosis o Lead to digoxin tox
36
K-Sparing Diuretics; Drug, area, MOA
Drugs o Amiloride Site o Distal Tubules MOA o Block Na channels o Less K excreted into lumen
37
K-Sparing Diuretics; Indications, Toxicity
Indications o Uncommon in vet med o Combine w/ loop or thiazide to decrease K wasting o Edema in hepatic encephalopathy Toxicity o hyperkalemia
38
Renal Secondary Hyperparathyroidism Basics
• Less functional kidney (decreased GFR) 
 • Phosphorus is not excreted 
 • High phos causes low iCa 
 • PTH release stimulated 
 • Phos still high so keeps stimulating PTH release 
 • Increased PTH causes increased Ca 
 • Parathyroid hyperplasia develops • treated w/ calcitrol
39
Calcitrol; MOA, Toxicity, Form, Monitoring
MOA • Replaces activated vit D • Improves GI Ca absorption • Inhibits PTH production Toxicity • Hypercalcemia • Tissue mineralization • Do not use if serum P >6 Form • Large capsule Monitoring • Ca, P, & PTH
40
Erythrocyte Stimulating Agents; Drugs, MOA, Indications, Toxicity, Form, Monitoring
Drugs o Epoetin alfa o Darbepoetin alfa MOA o Directly replace EPO to stimulate RBC production Inidcations o Clinical anemia Toxicity o Polycythemia o Hypertension o Autoantibody formation Delivery Form & monitoring o Injectable o Should give w/ Fe supplement o Monitor PCV
41
Opiates Used for Anti-tussives
Morphine • Poor bioavailability in dogs Codeine • less addictive • Poor bioavailability in dogs Hydrocodone • similar to codeine Butorphanol • FDA approved • most used • poor oral bioavailability but oral dosing achieves therapeutic levels
42
Opiates as Anti-tussives; MOA, Indications, Toxicity
MOA • Directly depress cough center in the medulla via either mu or kappa opiate receptors Indications • Moderate to severe coughing that interferes with patient’s quality of life Toxcicity • Potential for abuse
 • Sedation
 • Constipation
 • Respiratory depression (less of a problem with butorphanol) • Excitation/dysphoria in cats and horses (except butorphanol)
43
Dextromethorphan; Basics, MOA, Indications, Toxicity
o Anti-tussive o Many OTC formulations should not be used in animals o Poor oral bioavailability & short half-life in dogs MOA • Unknown • dextromethorphan is an opiate derivative but does not stimulate opiate receptors Indications • Moderate to severe coughing that interferes with patient’s quality of life Toxicity • Vomiting and CNS toxicity at high doses (dogs and cats)
44
Tramadol; Basics, MOA, Indications, Toxicity
o Non-opiate anti-tussive o NOT a controlled substance
 o Has greater oral bioavailability than true opiates MOA • Non-opiate that is a partial mu agonist, serotonin and alpha‐2 activity Indications • Moderate to severe coughing that interferes with patient’s quality of life. Toxicity • Sedation, nausea, vomiting • Efficacy reduced w/ drugs that inhibit CYP 2D
45
Uses & MOA for Bronchodilators
o reactive airway disease in cats (feline asthma) o recurrent airway obstruction (heaves in horses) o chronic obstructive airway disease and inflammatory airways disease (horses) o allergic bronchitis in dogs MOA o inhibition of phosphodiesterase (PDE)
 o Adenosine receptor antagonists
46
Methylxanthines; Class, Indications, Toxicity, interactions
o Bronchodilators Indications • Feline asthma • Canine allergic bronchitis • Recurrent airway obstruction horses (heaves/COPD) • Does not work in cattle Toxicity • CNS stimulation (limits use in horses) • Tachycardia
 • Nausea/vomiting
 • mild diuresis Drug-drug Interactions • Fluroquinolones & cimetidine inhibit CYP 450 & cause methylxanthine toxicity • Phenobarbital & rifampicin induce CYP and reduce methylxanthine conc. Drugs • Theophylline
47
Beta 2 Adrenergic Agonists; MOA, Drugs, Toxicity
MOA • increases intracellular cAMP and causes relaxation of smooth muscle • increase mucociliary clearance • short-acting used in emergencies • long-acting used for chronic conditions Drugs • Terbutaline • Metaproterenol • Albuterol (short acting) • Salmeterol (long acting; 12hrs) • Clenbuterol (long acting 6-8hrs) Toxicity • Short-acting agents stimulate alpha & beta 1 & 2 -> tachycardia • Beta-2 at high doses also stimulate Beta 1 -> cardiac toxicity • Tolerance to beat agonists occurs • Clenbuterol -> muscle tremors, sweating in horses • Tocolytic effects (anti-contraction of uterus) • Hypokalemia
48
Anticholinergics; MOA, Indications, Toxicity, Drugs
MOA • Inhibit muscarinic receptor type 3 Indications • Short-term bronchodilation Toxicity • Tachycardia • ileus, constipation, dry mouth • decreased mucocilliary clearance • CNS excitation leading to coma Drugs • Atropine - Crosses BBB • Glycopyrrolate - IV does not cross BBB • Ipratropium bromide - Aerosol not absorbed from drugs -> no systemic effects
49
Cromolyn; Route, MOA, Indications
Route • Inhalation/nebulization MOA • Inhibits mast cell degranulation by interfering with Ca transport across cell membrane. • Has no bronchodilator effects Indications • Must be administered prior to exposure to allergen
50
Corticosteroids; MOA, Indications, Toxicity, Drugs
MOA • Produces lipocortin -> blocks PLA2 • Decrease inflammation • Augment beta-2 bronchial smooth muscle relaxation • Prevent downregulation of beta-2 adrenergic receptors Indications • Inhalation for feline asthma • Allergic bronchitis • Non-septic pulmonary dz • Horses in resp distress Toxicity • Dogs – weight gain, Gi ulcers, secondary infections • Cats – weight gain, hyperglycemia, secondary infections • Horses – maybe laminitis Drugs • Prednisone(dogs) / prednisolone(cats/horses) – PO • Methylprednisolone acetate – IM • Dexmethasone – PO horses ONLY
51
Expectorants; Indications, Drugs
Indications • Increase output of bronchial secretions / decrease viscosity Drugs • Saline – vagally mediated reflex on gastric mucosa • Guaifenesin – vagal stimulation on bronchial secretion
52
Doxapram; MOA, Indications
MOA • Stim resp center of brain • Also might stim carotid & aortic chemoreceptors Indications • Use Stimulate respiratory center in emergency situations • Anesthetic emergencies • Overdoses‐opiates, benzodiazepines, macrocyclic lactones • Neonates • Laryngeal exam
53
Acetylcysteine MOA
• Mucolytic effects • Breaks disulfide bonds on mucoproteins
54
Sildenafil & Tadalafil MOA
• Type V phosphodiesterase inhibitor -> • nitric oxide production -> • dilate vessels in lungs
55
Use for Pseudoephedrine
decongestant